Exchange: NASDAQ·Updated 07:55 PM EDT
PRME logo

PRMEPrime Medicine Inc

$3.78
$0.45
(10.64%)
Today
Closed $3.78
$0.03
(0.79%)
After Hours
EarningsAug 6
Mkt Cap$682.73M
Vol6.66M
News
all
press releases
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.read more...
Benzinga
News Placeholder
More News
News Placeholder
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug
An independent arbitration panel ruled that developing Prime Medicine’s experimental drug for Alpha-1 Antitrypsin Deficiency falls within its rights under a 2019 collaboration agreement with Beam Therapeutics.
Stocktwits
News Placeholder
Here's Why H.C. Wainwright Upgraded Prime Medicine (PRME) To "Buy"
Here's Why H.C. Wainwright Upgraded Prime Medicine (PRME) To "Buy...
Yahoo! Finance: News
News Placeholder
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?
Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
News Placeholder
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsOcular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli...
Nasdaq News: Markets
News Placeholder
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -15.99% and -45.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
RenovoRx (RNXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings and Revenues Miss Estimates
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of -27.94% and -3.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Prime Medicine (NASDAQ:PRME) Upgraded to Sell at Wall Street Zen
Wall Street Zen raised shares of Prime Medicine from a "strong sell" rating to a "sell" rating in a research note on Tuesday...
MarketBeat
News Placeholder
Prime Medicine (NASDAQ:PRME) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded shares of Prime Medicine from a "sell" rating to a "strong sell" rating in a research report on Monday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.